TRIDENT: Triple Antihypertensive Pill Cuts Recurrent Stroke in ICH

Why It Matters

Improved blood‑pressure control after ICH directly lowers the risk of repeat stroke, addressing a major unmet therapeutic gap and offering clinicians a ready‑to‑use, FDA‑cleared option.

Key Takeaways

• Triple low‑dose pill cut recurrent stroke risk by 39%
• Mean systolic BP 127 mm Hg vs 138 mm Hg control
• Number needed to treat: 35 patients to prevent one stroke
• Adverse events similar, but discontinuations higher due to hypotension
• FDA‑approved formulation paves way for US clinical adoption

Pulse Analysis

Blood‑pressure management remains the cornerstone of secondary prevention after intracerebral hemorrhage (ICH), yet clinicians have long struggled with fragmented regimens and therapeutic inertia. The TRIDENT trial, enrolling 1,670 survivors across ten countries, tested a fixed‑dose combination of telmisartan, amlodipine and indapamide—three proven antihypertensives at low doses—in a single daily pill. By simplifying therapy, the study aimed to overcome adherence barriers that have hampered intensive BP control in this high‑risk population.

Results published in the New England Journal of Medicine demonstrate a clear clinical benefit. Patients receiving the triple pill achieved an average systolic pressure of 127 mm Hg, markedly lower than the 138 mm Hg observed in the placebo arm, translating into a 39% relative reduction in recurrent stroke (4.6% vs 7.4%). The absolute risk reduction yields a number needed to treat of 35, a compelling figure for health systems seeking cost‑effective stroke prevention. Although overall serious adverse events were comparable, the pill group experienced more treatment discontinuations, primarily due to hypotension and modest creatinine elevations, underscoring the need for careful monitoring.

The trial’s implications extend beyond the headline numbers. With the GMRx2 formulation already cleared by the FDA, U.S. providers can integrate this regimen into standard post‑ICH care without awaiting further regulatory steps. However, achieving broader BP targets will likely require complementary strategies—home monitoring, patient education, and multidisciplinary care pathways—to push control rates above the current 50% threshold. Future research may explore adding a fourth agent or tailoring doses to individual genetic and dietary profiles, but the TRIDENT findings already mark a decisive shift toward fixed‑dose combination therapy as a pragmatic, evidence‑based tool for reducing the devastating burden of repeat hemorrhagic stroke.